Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19
Status:
Recruiting
Trial end date:
2022-02-20
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, double-blind phase I clinical study of
anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS) to evaluate the safety and
antiviral efficacy for the treatment of adult patients with mild COVID-19 and low risk of
disease progression.